Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prediction Model for Freedom from TLR from a Multi-study Analysis of Long-Term Results with the Zilver PTX Drug-Eluting Peripheral Stent.
Dake MD, Fanelli F, Lottes AE, O'Leary EE, Reichert H, Jiang X, Fu W, Iida O, Zen K, Schermerhorn M, Zeller T, Ansel GM. Dake MD, et al. Among authors: lottes ae. Cardiovasc Intervent Radiol. 2021 Feb;44(2):196-206. doi: 10.1007/s00270-020-02648-6. Epub 2020 Oct 6. Cardiovasc Intervent Radiol. 2021. PMID: 33025243 Free PMC article.
Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study.
Dake MD, Scheinert D, Tepe G, Tessarek J, Fanelli F, Bosiers M, Ruhlmann C, Kavteladze Z, Lottes AE, Ragheb AO, Zeller T; Zilver PTX Single-Arm Study Investigators. Dake MD, et al. Among authors: lottes ae. J Endovasc Ther. 2011 Oct;18(5):613-23. doi: 10.1583/11-3560.1. J Endovasc Ther. 2011. PMID: 21992630
Impact of Chronic Renal Failure on Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease: Subgroup Analysis from Zilver PTX Post-Market Surveillance Study in Japan.
Ogawa Y, Yokoi H, Ohki T, Kichikawa K, Nakamura M, Komori K, Nanto S, O'Leary EE, Lottes AE, Saunders AT, Dake MD. Ogawa Y, et al. Among authors: lottes ae. Cardiovasc Intervent Radiol. 2017 Nov;40(11):1669-1677. doi: 10.1007/s00270-017-1673-6. Epub 2017 May 9. Cardiovasc Intervent Radiol. 2017. PMID: 28488101 Free PMC article.
Long-Term Effectiveness of the Zilver PTX Drug-Eluting Stent for Femoropopliteal Peripheral Artery Disease in Patients with No Patent Tibial Runoff Vessels-Results from the Zilver PTX Japan Post-Market Surveillance Study.
Cipollari S, Yokoi H, Ohki T, Kichikawa K, Nakamura M, Komori K, Nanto S, O'Leary EE, Lottes AE, Saunders AT, Dake MD. Cipollari S, et al. Among authors: lottes ae. J Vasc Interv Radiol. 2018 Jan;29(1):9-17.e1. doi: 10.1016/j.jvir.2017.08.014. Epub 2017 Nov 7. J Vasc Interv Radiol. 2018. PMID: 29122449 Free article.
Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results.
Kichikawa K, Ichihashi S, Yokoi H, Ohki T, Nakamura M, Komori K, Nanto S, O'Leary EE, Lottes AE, Snyder SA, Dake MD. Kichikawa K, et al. Among authors: lottes ae. Cardiovasc Intervent Radiol. 2019 Mar;42(3):358-364. doi: 10.1007/s00270-018-2110-1. Epub 2018 Nov 8. Cardiovasc Intervent Radiol. 2019. PMID: 30411151 Free PMC article.
Paclitaxel-Coated Zilver PTX Drug-Eluting Stent Treatment Does Not Result in Increased Long-Term All-Cause Mortality Compared to Uncoated Devices.
Dake MD, Ansel GM, Bosiers M, Holden A, Iida O, Jaff MR, Lottes AE, O'Leary EE, Saunders AT, Schermerhorn M, Yokoi H, Zeller T. Dake MD, et al. Among authors: lottes ae. Cardiovasc Intervent Radiol. 2020 Jan;43(1):8-19. doi: 10.1007/s00270-019-02324-4. Epub 2019 Sep 9. Cardiovasc Intervent Radiol. 2020. PMID: 31502026 Free PMC article. Clinical Trial.
22 results